Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19466965 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-Cell Lymphoma
Intervention: Drug: SGN-30 (anti-CD30 mAb)

Indicates status has not been verified in more than two years